The DOI matches its Crossref record; 22 of the 23 references it cites were found in a registry or an index.
Switching to dolutegravir plus rilpivirine versus maintaining current antiretroviral therapy regimen in virologically suppressed people with HIV-1 and the Lys103Asn (K103N) mutation: 48-week results from a randomised, open-label pilot clinical trial
Open accessAbstract
Background The combination of dolutegravir plus rilpivirine has been studied in people with virologically suppressed HIV with no previous history of treatment failure or resistance. We investigated the potential to maintain viral suppression with dolutegravir plus rilpivirine in people with Lys103Asn mutations whose HIV was previously managed with other treatment regimens. Methods In this open-label pilot trial at 32 clinical sites in seven European countries, virologically suppressed, HBsAg-negative adults aged 18 years or older with HIV-1 and Lys103Asn mutations were randomly assigned (2:1) to switch to 50 mg dolutegravir plus 25 mg rilpivirine (given as a single tablet) once daily or to continue their current antiretroviral therapy regimen (control group). After 48 weeks, participants in the control group also switched to dolutegravir plus rilpivirine. Randomisation was stratified by country, and a computer-generated randomisation list with permuted blocks within strata was used to assign participants to treatment groups. The primary endpoints were virological failure (ie, two consecutive measurements of 50 copies or more of HIV RNA per mL at least 2 weeks apart) and virological suppression (the proportion of participants with fewer than 50 copies of HIV RNA per mL) at week 48 (week 96 data will be reported separately). Analyses were done in the modified intention-to-treat population, which included all participants who received at least one dose of the study medication. T…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The current standard of care is highly active antiretroviral therapy, which typically combines multiple drug classes, including nucleoside reverse transcriptase inhibitors (Tenofovir, Lamivudine, Abacavir), non-nucleoside reverse transcriptase inhibitors (Rilpivirine), and integrase strand transfer inhibitors (Dolutegravir) (71, 72). This combination effectively suppresses viral replication, rest”
From Research progress on HIV-1 structural proteins and antiviral therapies (2026) · cites this paper as [72]
Citations
Cites
The end of AIDS: HIV infection as a chronic disease
Deeks, S. G., Lewin, S. R., & Havlir, D. V. (2013) · The Lancet · doi:10.1016/s0140-6736(13)61809-7 · Cited by 2,063
UPDATE ON DRUG RESISTANCE MUTATIONS IN HIV-1
&NA; (2001) · Infectious Diseases in Clinical Practice · doi:10.1097/00019048-200106000-00020 · Cited by 1,660
Neural-Tube Defects with Dolutegravir Treatment from the Time of Conception
Zash, R., Makhema, J., & Shapiro, R. L. (2018) · New England Journal of Medicine · doi:10.1056/nejmc1807653 · Cited by 378
Llibre, J. M., Hung, C.-C., Brinson, C., Castelli, F., Girard, P.-M., Kahl, L. P., Blair, E. A., Angelis, K., Wynne, B., Vandermeulen, K., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(17)33095-7 · Cited by 358
Self-citationBacheler, L. T., Anton, E. D., Kudish, P., Baker, D., Bunville, J., Krakowski, K., Bolling, L., Aujay, M., Wang, X. V., Ellis, D., et al. (2000) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.44.9.2475-2484.2000 · Cited by 268
Randomization in Clinical Trials: Permuted Blocks and Stratification
Broglio, K. (2018) · JAMA · doi:10.1001/jama.2018.6360 · Cited by 243
Cahn, P., Madero, J. S., Arribas, J. R., Antinori, A., Ortiz, R., Clarke, A. E., Hung, C.-C., Rockstroh, J. K., Girard, P.-M., Sievers, J., et al. (2020) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0000000000002275 · Cited by 214
Self-citation(2013) · The Lancet · doi:10.1016/s0140-6736(13)61164-2 · Cited by 169
Tenofovir Effect on the Kidneys of HIV-Infected Patients: A Double-Edged Sword?
Tourret, J., Deray, G., & Bagnis, C. I. (2013) · Journal of the American Society of Nephrology · doi:10.1681/asn.2012080857 · Cited by 162
Osiyemi, O. O., Wit, S. D., Ajana, F., Bisshop, F., Portilla, J., Routy, J., Wyen, C., Ait‐Khaled, M., Leone, P. A., Pappa, K. A., et al. (2022) · Clinical Infectious Diseases · doi:10.1093/cid/ciac036 · Cited by 153
Self-citation
Cited by
Rashid, I., Unger, N. R., Willis, C., Dhippayom, T., Ramgopal, M. N., Sherman, E. M., Yared, N. F., Safran, R., Swiatlo, E., Weinberg, A. R., et al. (2025) · HIV Medicine · doi:10.1111/hiv.70050 · Cited by 6
Research progress on HIV-1 structural proteins and antiviral therapies
Wang, H., Yuan, J., & Wang, H. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1805597 · Cited by 2
The role of HIV biology in defining virological failure
Boyce, C. L., & Frenkel, L. M. (2024) · The Lancet HIV · doi:10.1016/s2352-3018(24)00033-x · Cited by 1
Moyle, G. J., Assoumou, L., Castro, N. D., Post, F. A., Curran, A., Rusconi, S., Wit, S. D., Stephan, C., Raffi, F., Johnson, M. A., et al. (2026) · AIDS · doi:10.1097/qad.0000000000004451 · Cited by 1
Self-citationPautas actuales de tratamiento de la infección por VIH
Arbaizar, J. F., Martínez, A. N., Revollo, B., & Llibre, J. M. (2025) · FMC - Formación Médica Continuada en Atención Primaria · doi:10.1016/j.fmc.2025.01.007
Metadata
- Authors
- Moyle, G., Assoumou, L., de Castro, N., Post, F. A., Curran, A., Rusconi, S., De Wit, S., Stephan, C., Raffi, F., Johnson, M., Masia, M., Vera, J., Jones, B., Grove, R., Fletcher, C., Duffy, A., Morris, K., Pozniak, A., Moyle, G., de Castro, N., Post, F., Curran, A., Rusconi, S., De Wit, S., Stephan, C., Raffi, F., Johnson, M., Masia, M., Vera, J., Winston, A., Kegg, S., Waters, L., Orkin, C., Ustianowski, A., Reeves, I., Leen, C., Perry, M., Portilla, J., Blanco, J. L., Montejaro, R., Domingo, P., Molina, J. M., Katlama, C., Morlat, P., Kenyon, C., Puoti, M., Rizzardini, G., Castagna, A., Castelli, F., Giacomelli, A., Rockstroh, J., Esser, S., Hoffmann, C., & Mallon, P.
- Affiliations
- Inserm (FR)
- ViiV Healthcare (United Kingdom) (GB)
- GlaxoSmithKline (United Kingdom) (GB)
- London School of Hygiene & Tropical Medicine (GB)
- University of Milan (IT)
- ORCID
- Assoumou, Lambert
- Jones, Bryn
- Grove, Richard
- Pozniak, Anton
- Winston, Alan
- Waters, Laura
- Ustianowski, Andrew
- Leen, Clifford
- Perry, Meghan
- Molina, Jean Michel
- Katlama, Christine
- Puoti, Massimo
- Rizzardini, Giuliano
- Castagna, Antonella
- Castelli, Francesco
- Giacomelli, Andrea
- Rockstroh, Jürgen
- Esser, Stefan
- Hoffmann, Christian
- Mallon, Patrick
- Venue
- The Lancet HIV
- Publisher
- Elsevier BV
- Published
- 2024-03
- Volume
- 11
- Issue
- 3
- Pages
- e156-e166
- ISSN
- 2352-3018 (ISSN-L)
- OpenAlex
- W4392180047
- Cited by
- 6
- References
- 23
- Citations by year
- 2026: 3 · 2025: 2 · 2024: 1
- FWCI
- 2.08
- Type
- journal article
- Language
- en
- Open access
- green
- figshare.com
- Licence
- cc-by
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- doi.org/10.15223/policy-017 (stm-asf)
- doi.org/10.15223/policy-037 (stm-asf)
- doi.org/10.15223/policy-012 (stm-asf)
- doi.org/10.15223/policy-029 (stm-asf)
- doi.org/10.15223/policy-004 (stm-asf)
- Locations
- The Lancet HIV (publishedVersion)
- PubMed (publishedVersion)
- Figshare (submittedVersion, cc-by)
- Institutional Research Information System (Università degli Studi di Brescia) (submittedVersion)
- Funders
- ViiV Healthcare UK
- Topics
- Health Sciences › Medicine › Infectious Diseases › HIV/AIDS drug development and treatment
- Health Sciences › Medicine › Infectious Diseases › HIV/AIDS Research and Interventions
- Life Sciences › Immunology and Microbiology › Virology › HIV Research and Treatment
- Keywords
- rilpivirine, HIV-1, K103N mutation, integrase inhibitor resistance, antiretroviral therapy switching, viral suppression, virological failure, integrase inhibitors, single-tablet regimen
- MeSH terms
- Rilpivirine, Dolutegravir, Adult, Heterocyclic Compounds, 3-Ring, HIV Seropositivity, Humans, Mutation, Oxazines, Pilot Projects, Piperazines, Pyridones, RNA, HIV-1, HIV Infections, Treatment Outcome, Anti-HIV Agents, Viral Load, Anti-Retroviral Agents
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Switching to dolutegravir plus rilpivirine versus maintaining current antiretroviral therapy regimen in virologically suppressed people with HIV-1 and the Lys103Asn (K103N) mutation: 48-week results from a randomised, open-label pilot clinical trial. https://app.cochat.ai/papers/10.1016/s2352-3018(23)00292-8
- The paper
- Moyle, G., Assoumou, L., de Castro, N., Post, F. A., Curran, A., Rusconi, S., De Wit, S., Stephan, C., Raffi, F., Johnson, M., Masia, M., Vera, J., Jones, B., Grove, R., Fletcher, C., Duffy, A., Morris, K., Pozniak, A., Moyle, G., . . . Mallon, P. (2024). Switching to dolutegravir plus rilpivirine versus maintaining current antiretroviral therapy regimen in virologically suppressed people with HIV-1 and the Lys103Asn (K103N) mutation: 48-week results from a randomised, open-label pilot clinical trial. The Lancet HIV. https://doi.org/10.1016/s2352-3018(23)00292-8
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.